AUG 07, 2018 11:00 PM PDT

Can a Myeloid Marker Be Helpful in B-cell Neoplasm Diagnostic Testing?

WRITTEN BY: Mauri Brueggeman

Diagnostic testing for hematologic and other cancers has been a traditional method of evaluating, diagnosing, and providing prognostic information to providers choosing treatment and options for oncology patients.  Molecular diagnostics, in particular, have jumped to the forefront of diagnostic testing to provide not only a diagnosis, but to also evaluate the biomarkers present in particular groups of cells; biomarker identification predicts disease behavior, helps in selection of therapeutic treatment targets and options, assists in stratification of disease, and provides a personalized medicine approach. 

Immunophenotyping has become an invaluable diagnostic tool used by clinicians and hematopathologists to fit cancers into appropriate subgroups based on the biomarkers present on tumor involved cell lines. 

There are a multitude of B-cell neoplasms including multiple myeloma, chronic lymphocytic leukemia, small lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, Burkitt’s lymphoma, Mantle cell lymphoma, and others.  In these cases, because they are lymphoid in origin, it is unexpected to find myeloid markers, however, researchers at Stanford and Oregon Health Sciences in Portland found that CD13, a myeloid marker, is expressed in a subset of lymphomas which can be helpful in differentiating between B-cell neoplasms in the clinical setting.

The group published their findings in the International Journal of Laboratory Hematology, which outlined their analysis of 286 mature B-cell neoplasms after immunophenotyping was completed.  CD13 expression was found in cases of lymphoplasmacytic lymphoma (LPL) (61.5% of cases) and FMC7-positive chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (37% of cases).  Notably, there were no cases of follicular lymphoma that expressed CD13. 

The group concluded that CD13 expression is usually present in LPL and FMC7-positive CLL or SLL and is not found in FL.  Historically, CD13 has not been used to characterize B-cell neoplasm subtypes but could be a useful diagnostic means to aid in neoplasm subtyping and furthering B-cell neoplasm therapeutic targeting.

Sources: International Journal of Laboratory Hematology, Archives of Pathology & Laboratory Medicine, Clinics in Oncology , Modern Pathology 

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
NOV 04, 2020
Cancer
Building a New Chemotherapy Drug
NOV 04, 2020
Building a New Chemotherapy Drug
For decades, modern medicine has relied on chemists’ work to produce compounds that could one day be used as a dru ...
NOV 26, 2020
Clinical & Molecular DX
Routine Diagnostic Tests Linked to a 59 Percent Increase in Testicular Cancer Risk
NOV 26, 2020
Routine Diagnostic Tests Linked to a 59 Percent Increase in Testicular Cancer Risk
New research has revealed that exposure to radiation from diagnostic procedures such as X-rays could contribute to an el ...
DEC 09, 2020
Cancer
Fertility after breast cancer
DEC 09, 2020
Fertility after breast cancer
New data presented at the 2020 San Antonio Breast Cancer Symposium this week dives into the complexities of fertility af ...
DEC 14, 2020
Cancer
Fibronectin Could Act as a Biomarker for Early Prognosis of Live Cancer
DEC 14, 2020
Fibronectin Could Act as a Biomarker for Early Prognosis of Live Cancer
Diagnostics is one of the key pillars of modern medicine. Diagnostics allows patients and doctors to identify a problem ...
JAN 11, 2021
Cancer
Sentinel Nodes Could Reveal a Tumor's Prognosis
JAN 11, 2021
Sentinel Nodes Could Reveal a Tumor's Prognosis
For many diseases, the ability to quickly and effectively diagnose or prognose a patient is critical. If caught early on ...
JAN 12, 2021
Cancer
The frightening association between oral sex and HPV-related cancers
JAN 12, 2021
The frightening association between oral sex and HPV-related cancers
New research published recently in the online edition of CANCER, a peer-reviewed journal of the American Cancer Soc ...
Loading Comments...